Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT04227847
PHASE1

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

Sponsor: Seagen, a wholly owned subsidiary of Pfizer

View on ClinicalTrials.gov

Summary

This trial will look at a drug called SEA-CD70 with and without azacitidine, to find out if it is safe for participants with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). It will study SEA-CD70 to find out what its side effects are and if it works for AML and MDS. A side effect is anything the drug does besides treating cancer. This study will have seven groups or "parts." * Part A will find out how much SEA-CD70 should be given to participants * Part B will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat participants with MDS. * Part C will use the dose found in Part A to find out how safe SEA-CD70 is and if it works to treat participants with AML. * Part D will find out how much SEA-CD70 with azacitidine should be given to participants * Part E will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat participants with MDS or MDS/AML that has not been treated. * Part F will use the dose found in Part D to find out how safe SEA-CD70 with azacitidine is and if it works to treat participants with MDS or MDS/AML. * Part G will find out how much SEA-CD70 with azacitidine and with venetoclax should be given to participants with AML. Also, to evaluate safety and tolerability of PF-08046040 in combination with azacitidine and venetoclax in participants with previously untreated AML who are unfit for standard induction chemotherapy.

Official title: A Phase 1 Study of SEA-CD70 in Myeloid Malignancies

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

178

Start Date

2020-08-07

Completion Date

2028-07-03

Last Updated

2026-04-07

Healthy Volunteers

No

Interventions

DRUG

SEA-CD70

Given into the vein (IV; intravenously) on Days 1 and 15 of each treatment cycle

DRUG

azacitidine

75mg/m\^2 injected under the skin (SC; subcutaneous) or given into the vein (IV; intravenously) on Days 1 through 7 of each treatment cycle.

DRUG

Venetoclax

400 mg /day PO, continuously; administered with ramping

Locations (54)

University of Alabama at Birmingham

Birmingham, Alabama, United States

University of Alabama at Birmingham

Birmingham, Alabama, United States

Dept. of Medicine, UAB ONeal Comprehensive Cancer Center

Birmingham, Alabama, United States

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Duarte, California, United States

IP Address: City of Hope Investigational Drug Services(IDS)

Duarte, California, United States

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

UCLA Hematology-Oncology Clinic

Los Angeles, California, United States

Colorado Blood Cancer Institute, Lab

Denver, Colorado, United States

Colorado Blood Cancer Institute

Denver, Colorado, United States

Presbyterian/St. Luke's Medical Center

Denver, Colorado, United States

The University of Kansas Cancer Center ,Investigational Drug Services

Fairway, Kansas, United States

The University of Kansas Clinical Research Center

Fairway, Kansas, United States

The University of Kansas Hospital

Kansas City, Kansas, United States

University of Kansas Hospital Cambridge North Tower A

Kansas City, Kansas, United States

University of Kansas Medical center Medical office building

Kansas City, Kansas, United States

University of Kansas Medical Center Research Institute

Kansas City, Kansas, United States

The University of Kansas Cancer Center - Overland Park

Overland Park, Kansas, United States

The University of Kansas Cancer Center - Indian Creek Campus

Overland Park, Kansas, United States

The University of Kansas Cancer Center

Westwood, Kansas, United States

Norton Hospitals, Inc

Louisville, Kentucky, United States

Norton Cancer Institute, St. Matthews Campus, Attn. Becky Champion, PharmD

Louisville, Kentucky, United States

Norton Cancer Institute, St. Matthews Campus

Louisville, Kentucky, United States

Norton Women & Children's Hospital

Louisville, Kentucky, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Dana Farber/Mass General Brigham Cancer Care, Inc

Boston, Massachusetts, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

Karmanos Cancer Institute Weisberg Cancer Treatment Center

Farmington Hills, Michigan, United States

The University of Kansas Cancer Center - Medical Oncology Clinic

Kansas City, Missouri, United States

The University of Kansas Cancer Center - Radiation Oncology Clinic

Kansas City, Missouri, United States

The University of Kansas Cancer Center -North

Kansas City, Missouri, United States

The University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, United States

Columbia University Irving Medical Center

New York, New York, United States

CUIMC Research Pharmacy

New York, New York, United States

The New York and Presbyterian Hospital

New York, New York, United States

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

The Ohio State University Wexner Medical Center/James Cancer Hospital

Columbus, Ohio, United States

Hollings Cancer Center

Charleston, South Carolina, United States

Medical University of South Carolina- Ashley River Tower

Charleston, South Carolina, United States

Medical University of South Carolina- Investigational Drug Services

Charleston, South Carolina, United States

Medical University of South Carolina- University Hospital

Charleston, South Carolina, United States

Baylor Research Institute

Dallas, Texas, United States

Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy

Dallas, Texas, United States

Baylor University Medical Center

Dallas, Texas, United States

Houston Methodist Hospital

Houston, Texas, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Swedish Cancer Institute

Seattle, Washington, United States

Swedish Medical Center

Seattle, Washington, United States

National Cancer Center Hospital East

Kashiwa, Chiba, Japan

Nippon Medical School Hospital

Bunkyo-ku, Tokyo, Japan

Yamagata University Hospital

Yamagata, Japan

Pharmacy - UMC Utrecht t.a.v. Apotheek KGO

Utrecht, Netherlands

University Medical Center (UMC) Utrecht

Utrecht, Netherlands